Role of Combination Therapy in Respiratory Conditions

Benefits of Combination Therapy

Adding Advair (fluticasone/salmeterol) after completing oral prednisone therapy is strongly recommended for patients with chronic respiratory conditions to maintain improved lung function, reduce risk of relapse, and prevent future exacerbations 1
Initiating Advair after oral prednisone helps maintain the improved lung function achieved during the acute treatment phase 1

Following acute treatment with oral corticosteroids, maintenance therapy with a combination inhaled corticosteroid/long-acting beta agonist helps prevent future exacerbations 2

The European Respiratory Society/American Thoracic Society guidelines recommend a short course (≤14 days) of oral corticosteroids for COPD exacerbations 2
After completing oral prednisone, Advair should be initiated at an appropriate dose based on disease severity 3
For moderate persistent asthma, a low-dose inhaled corticosteroid plus long-acting beta agonist (Step 3 therapy) is the preferred maintenance treatment, as recommended by the American Academy of Family Physicians 3

Blood eosinophil count may help predict response to corticosteroid therapy - patients with counts ≥2% show better response to corticosteroids 1
Regular monitoring of lung function, symptom control, and exacerbation frequency is essential to assess treatment efficacy, as recommended by the American Thoracic Society 4

Long-acting beta agonists should never be used as monotherapy for asthma; they should always be used in combination with inhaled corticosteroids, as recommended by the American Academy of Family Physicians 3
The combination of fluticasone/salmeterol in Advair provides both symptom control and reduction in exacerbation risk, addressing both aspects of respiratory disease management 4